Lactylation Targeting Shows Preclinical Anti-Fibrotic Potential in Liver FibrosisNew Research Identifies Potential Targets for Liver Fibrosis Treatment
Frontiers in MedicinePublished September 29, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider lactylation as a preclinical target; clinical relevance is unconfirmed.
This narrative review synthesizes preclinical evidence on lactylation, specifically histone H3K18La, as a potential mechanism in liver fibrosis. The authors propose that H3K18La converges on several pathways, including HK2-KAT8, IGF2BP2-N6-methyladenosine-ALDOA, and HKDC1-ORMDL3, which may drive pro-fibrotic transcriptional programs.
The review describes interventions targeting lactate-metabolizing enzymes (HK2, LDH), lactylation writers (KAT8), and specific lactylation sites (PGK1-K353 interfering peptides) that demonstrated anti-fibrotic potential in preclinical models. Natural products curcumol, limonin, and salidroside are noted for multi-target regulatory advantages.
No effect sizes, sample sizes, or statistical significance data were reported. Safety outcomes, including adverse events and tolerability, were not reported. The authors acknowledge that the review is limited to preclinical models, and funding or conflicts of interest were not reported.
The review provides a framework for future site-specific interventions, cell type-resolved lactylomics, and molecular subtyping-driven clinical trials. However, certainty for clinical application is low because findings are based on preclinical models and narrative synthesis. H3K18La as a clinical target and the efficacy of natural products in humans should not be overstated.
How this fits prior evidence
This review extends prior preclinical coverage of liver fibrosis therapies, including macrophage reprogramming and Dioscin, by focusing on lactylation as a mechanistic target. It aligns with prior coverage of salidroside in animal models of NAFLD and diabetic nephropathy, where clinical verification remains unconfirmed. Unlike the systematic review and meta-analysis of AI models for MASH and fibrosis diagnosis, this narrative review does not provide diagnostic accuracy data. The findings remain preclinical, consistent with the cautious framing of prior related reviews.
Researchers reviewed how a specific chemical process called lactylation affects liver fibrosis. They found that certain enzymes and proteins involved in this process may drive the scarring of liver tissue. This review looked at how targeting these specific areas could potentially stop the progression of liver disease.
In early laboratory tests, several interventions showed potential to reduce fibrosis. These included targeting specific enzymes like HK2 and LDH, as well as using certain peptides. Additionally, natural compounds such as curcumol, limonin, and salidroside were noted for their ability to regulate multiple targets in the body.
It is important to note that these findings come from preclinical models, which means they were tested in laboratory settings rather than in humans. Because the evidence is currently limited to early research, these results do not yet provide a clear path for clinical treatment. Patients should consult their doctors regarding current treatments for liver conditions.
What this means for you:
Early laboratory studies show potential targets for liver fibrosis, but more human research is needed.
Common questions
What are the natural products being studied for liver health?
The review highlights three specific natural products: curcumol, limonin, and salidroside. These compounds were noted for their multi-target regulatory advantages in the study. However, because these findings are based on preclinical models, their effectiveness in humans is not yet known.
What is the role of lactylation in liver fibrosis?
Lactylation, specifically H3K18La, is proposed to drive the programs that cause liver scarring. The research suggests that this process involves several pathways and enzymes. By targeting these specific pathways, scientists hope to find ways to stop the progression of liver fibrosis.
Are these treatments currently available for patients?
No, these treatments are not currently available for patients. The findings are based on a narrative review of preclinical models, which means they were tested in a lab setting. More research is needed to determine if these interventions are safe and effective for people with liver disease.
Metabolic reprogramming and epigenetic remodeling of hepatic stellate cells (HSCs) represent central driving events in liver fibrosis. Lactylation, a lactate-mediated post-translational modification (PTM), is proposed to converge on histone H3 lysine 18 lactylation (H3K18La) through the HK2-KAT8 positive feedback loop, the IGF2BP2-N6-methyladenosine (m6A)-aldolase A (ALDOA) cascade, and the HKDC1-ORMDL3 pathway, potentially driving pro-fibrotic transcriptional programs in a synergistic manner. H3K18La does not operate in isolation; its site-specific competition with acetylation, cascade amplification with m6A methylation, cooperation with G9a/DNMT1-mediated methylation, and antagonism with ubiquitination form a PTM interaction network. Therapeutically, interventions targeting lactate-metabolizing enzymes (HK2, LDH), lactylation writers (KAT8), and specific lactylation sites (PGK1-K353 interfering peptides) have demonstrated anti-fibrotic potential in preclinical models. Natural products including curcumol, limonin, and salidroside exhibit multi-target regulatory advantages. Muscle-derived SORBS3 lactylation-mediated trans-organ signaling and lactylation gene-based molecular subtyping expand the systemic dimensions of lactylation. This narrative review proposes a working hypothesis positioning H3K18La as a metabolic-epigenetic convergence node and outlines future directions including site-specific interventions, cell type-resolved lactylomics, and molecular subtyping-driven clinical trials, providing an integrated framework from basic research to translational applications for liver fibrosis.
